These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 10875063

  • 1. [Extrapyramidal side effects of neuroleptic and antidepressant treatment: assessment of potential risk factors through CYP2D6 genetic polymorphism].
    Reggiani K, Vandel P, Haffen E, Sechter D, Bizouard P, Vandel S.
    Encephale; 2000; 26(1):62-7. PubMed ID: 10875063
    [Abstract] [Full Text] [Related]

  • 2. Drug extrapyramidal side-effects or not: is there a dextromethorphan phenotype difference?
    Vandel P, Haffen E, Vandel S, Bonin B, Sechter D, Bizouard P, Dalery J.
    Therapie; 2000; 55(3):349-53. PubMed ID: 10967711
    [Abstract] [Full Text] [Related]

  • 3. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
    Plesnicar BK, Zalar B, Breskvar K, Dolzan V.
    J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
    [Abstract] [Full Text] [Related]

  • 4. CYP2D6 genotypes in Puerto Rican psychiatry patients with intolerance of antidepressants and antipsychotics.
    Gonzalez-Tejera GM, Corey S.
    Bol Asoc Med P R; 2009 Nov; 101(1):7-12. PubMed ID: 19954080
    [Abstract] [Full Text] [Related]

  • 5. Cyp2d6*3, *4, *5 and *6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving antipsychotic therapy.
    Crescenti A, Mas S, Gassó P, Parellada E, Bernardo M, Lafuente A.
    Clin Exp Pharmacol Physiol; 2008 Jul; 35(7):807-11. PubMed ID: 18346175
    [Abstract] [Full Text] [Related]

  • 6. CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study.
    Kobylecki CJ, Jakobsen KD, Hansen T, Jakobsen IV, Rasmussen HB, Werge T.
    Neuropsychobiology; 2009 Jul; 59(4):222-6. PubMed ID: 19521114
    [Abstract] [Full Text] [Related]

  • 7. The role of CYP2D6 and TaqI A polymorphisms in malignant neuroleptic syndrome: two case reports with three episodes.
    Zivković M, Mihaljević-Peles A, Sagud M, Silić A, Mihanović M.
    Psychiatr Danub; 2010 Mar; 22(1):112-6. PubMed ID: 20305604
    [Abstract] [Full Text] [Related]

  • 8. CYP 2D6 polymorphism and antipsychotic therapy.
    Plesnicar BK, Dolzan V, Zalar B.
    Psychiatr Danub; 2008 Sep; 20(3):369-71. PubMed ID: 18827765
    [Abstract] [Full Text] [Related]

  • 9. [CYP2D6 gene polymorphism in psychiatric patients resistant to standard pharmacotherapy].
    Zabrocka M, Woszczek G, Borowiec M, Rabe-Jabłońska J, Kowalski ML.
    Psychiatr Pol; 1999 Sep; 33(1):91-100. PubMed ID: 10786218
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes.
    Vandel P, Haffen E, Vandel S, Bonin B, Nezelof S, Sechter D, Broly F, Bizouard P, Dalery J.
    Eur J Clin Pharmacol; 1999 Nov; 55(9):659-65. PubMed ID: 10638395
    [Abstract] [Full Text] [Related]

  • 12. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline.
    Roberts RL, Mulder RT, Joyce PR, Luty SE, Kennedy MA.
    Hum Psychopharmacol; 2004 Jan; 19(1):17-23. PubMed ID: 14716707
    [Abstract] [Full Text] [Related]

  • 13. The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice.
    Mulder H, Herder A, Wilmink FW, Tamminga WJ, Belitser SV, Egberts AC.
    Pharmacoepidemiol Drug Saf; 2006 Feb; 15(2):107-14. PubMed ID: 16294366
    [Abstract] [Full Text] [Related]

  • 14. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study.
    Rau T, Wohlleben G, Wuttke H, Thuerauf N, Lunkenheimer J, Lanczik M, Eschenhagen T.
    Clin Pharmacol Ther; 2004 May; 75(5):386-93. PubMed ID: 15116051
    [Abstract] [Full Text] [Related]

  • 15. A CYP2D6 phenotype-genotype mismatch in Japanese psychiatric patients.
    Ieiri I, Yamada S, Seto K, Morita T, Kaneda T, Mamiya K, Tashiro N, Higuchi S, Otsubo K.
    Pharmacopsychiatry; 2003 Sep; 36(5):192-6. PubMed ID: 14571354
    [Abstract] [Full Text] [Related]

  • 16. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers.
    Aarnoutse RE, Kleinnijenhuis J, Koopmans PP, Touw DJ, Wieling J, Hekster YA, Burger DM.
    Clin Pharmacol Ther; 2005 Dec; 78(6):664-74. PubMed ID: 16338282
    [Abstract] [Full Text] [Related]

  • 17. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects.
    Wuttke H, Rau T, Heide R, Bergmann K, Böhm M, Weil J, Werner D, Eschenhagen T.
    Clin Pharmacol Ther; 2002 Oct; 72(4):429-37. PubMed ID: 12386645
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Retrospective assessment of the antidepressants tolerance in the group of patients with diagnosis of depression and different CYP2D6 genotype].
    Grzesiak M, Beszłej A, Lebioda A, Jonkisz A, Dobosz T, Kiejna A.
    Psychiatr Pol; 2003 Oct; 37(3):433-44. PubMed ID: 13677973
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.